Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
VESALIUS-CV data supported evolocumab reducing MACE in high-risk primary prevention diabetes over 4.8 years, reinforcing the ...
Pharmaceutical Executive: How does the complexity of obesity impact the effectiveness of GLP-1s? Mark Bagnall: This is one of ...
In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant bacterial threats, Roche and C4 Therapeutics expand ...
Air route diversions and constrained regional access are eroding schedule certainty for temperature-controlled air freight, ...
In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ...
Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...
Companion diagnostics (CDx), positioned at the intersection of pathology, drug development, and patient access, have emerged ...
The most immediate impacts of the U.S.- Iran conflict is being observed in the supply of active pharmaceutical ingredients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results